{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:23:55Z","timestamp":1790115835005,"version":"4.0.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Over the last 15 years, cancer drug prices have increased substantially in the United States (US), with question marks on whether this can be justified based on improved patient outcomes. This study aimed to analyze the relationship between US cancer drug net launch prices and clinical efficacy and certainty of evidence. FDA-approved cancer drug indications from 2008 to 2022 were extracted and matched with net launch price data, 5 distinct measures of clinical efficacy, and measures on the certainty of evidence around the clinical efficacy. Descriptive statistics and linear regression models were used to assess if higher net launch prices were associated with better patient outcomes. Cancer drug launch prices (net per 1 year\/course of treatment) have increased from around $100 000 in 2008 to $200 000 in 2022. The results did not support the idea that drugs with higher net launch prices had more impressive clinical efficacy or more robust evidence around the clinical efficacy. US cancer launch prices do not seem to be value-based, which may imply distorted incentives for the allocation of research and development investments.<\/jats:p>","DOI":"10.1093\/haschl\/qxaf051","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T16:24:23Z","timestamp":1741710263000},"source":"Crossref","is-referenced-by-count":2,"title":["An analysis of US net cancer drug launch prices and clinical efficacy and certainty of evidence from 2008 to 2022"],"prefix":"10.1093","volume":"3","author":[{"given":"Sumaya","family":"Abuloha","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida , Gainesville, Fl 32611 ,","place":["United States"]},{"name":"Department of Clinical Pharmacy and Pharmacy Practice, College of Pharmacy, Yarmouk University , Irbid, 21163 ,","place":["Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P","family":"Harvey","sequence":"additional","affiliation":[{"name":"Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg, 405 30 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5474-4263","authenticated-orcid":false,"given":"Shu","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida , ,","place":["Gainesville, Fl 32611 United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2551-5484","authenticated-orcid":false,"given":"Alaa","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida , ,","place":["Gainesville, Fl 32611 United States"]},{"name":"Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University , Dammam, 31451, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Miri","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida , ,","place":["Gainesville, Fl 32611 United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8027-0569","authenticated-orcid":false,"given":"Katherine","family":"Clifford","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Tufts Medical Center , Boston, MA 02111 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chambers","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Tufts Medical Center , Boston, MA 02111 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-7478","authenticated-orcid":false,"given":"Mikael","family":"Svensson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida ,","place":["Gainesville, Fl 32611, United States"]},{"name":"School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg , Gothenburg, 405 30 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"12","key":"2025040414261784300_qxaf051-B1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40273-022-01195-x","article-title":"Getting the price right: lessons for medicare price negotiation from peer countries","volume":"40","author":"Rand","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"2025040414261784300_qxaf051-B2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"2025040414261784300_qxaf051-B3","author":"OECD"},{"issue":"9","key":"2025040414261784300_qxaf051-B4","doi-asserted-by":"publisher","first-page":"e212026","DOI":"10.1001\/jamaoncol.2021.2026","article-title":"Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe","volume":"7","author":"Vokinger","year":"2021","journal-title":"JAMA Oncol"},{"issue":"8","key":"2025040414261784300_qxaf051-B5","doi-asserted-by":"publisher","first-page":"e223180","DOI":"10.1001\/jamahealthforum.2022.3180","article-title":"Improving prescription drug affordability through regulatory action","volume":"3","author":"Bush","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"8","key":"2025040414261784300_qxaf051-B6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.amjmed.2009.04.012","article-title":"Medical bankruptcy in the United States, 2007: results of a national study","volume":"122","author":"Himmelstein","year":"2009","journal-title":"Am J Med"},{"issue":"1","key":"2025040414261784300_qxaf051-B7","doi-asserted-by":"publisher","first-page":"e2144923","DOI":"10.1001\/jamanetworkopen.2021.44923","article-title":"Trends in prices of drugs used to treat metastatic non\u2013small cell lung cancer in the US from 2015 to 2020","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2025040414261784300_qxaf051-B8","doi-asserted-by":"publisher","first-page":"113042","DOI":"10.1016\/j.socscimed.2020.113042","article-title":"Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US","volume":"258","author":"Salas-Vega","year":"2020","journal-title":"Soc Sci Med"},{"issue":"3","key":"2025040414261784300_qxaf051-B9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/hec.3021","article-title":"Value-based differential pricing: efficient PRices for drugs in a global ContextA","volume":"24","author":"Danzon","year":"2013","journal-title":"Health Econ."},{"issue":"8","key":"2025040414261784300_qxaf051-B10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jval.2023.04.008","article-title":"How uncertainty matters under risk neutrality","volume":"26","author":"Glynn","year":"2023","journal-title":"Value Health"},{"issue":"6","key":"2025040414261784300_qxaf051-B11","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jval.2023.03.054","article-title":"P42 value-based pricing for drugs with accelerated approval incorporating uncertainty and risk aversion","volume":"26","author":"Jiao","year":"2023","journal-title":"Value Health."},{"key":"2025040414261784300_qxaf051-B12","author":"ICER"},{"issue":"10","key":"2025040414261784300_qxaf051-B13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/hec.3086","article-title":"The influence of cost-effectiveness and other factors on nice decisions","volume":"24","author":"Dakin","year":"2015","journal-title":"Health Econ."},{"issue":"12","key":"2025040414261784300_qxaf051-B14","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.jval.2022.05.006","article-title":"Differences in evidentiary requirements between European medicines agency and European health technology assessment of oncology drugs & can alignment be enhanced?","volume":"25","author":"Wolters","year":"2022","journal-title":"Value Health."},{"issue":"1","key":"2025040414261784300_qxaf051-B15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the market for anticancer drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J Econ Perspect."},{"issue":"3","key":"2025040414261784300_qxaf051-B16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1257\/app.4.3.167","article-title":"Drug innovations and welfare measures computed from market demand: the case of anti-cholesterol drugs","volume":"4","author":"Dunn","year":"2012","journal-title":"Am Econ J Appl Econ."},{"issue":"4","key":"2025040414261784300_qxaf051-B17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1377\/hlthaff.2014.0639","article-title":"Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains","volume":"34","author":"Lakdawalla","year":"2015","journal-title":"Health Affairs (Project Hope)"},{"issue":"10","key":"2025040414261784300_qxaf051-B18","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.6004\/jnccn.2020.7574","article-title":"Association between clinical value and financial cost of cancer treatments: a cross-sectional analysis","volume":"18","author":"Mitchell","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2025040414261784300_qxaf051-B19","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","article-title":"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015","volume":"28","author":"Vivot","year":"2017","journal-title":"Ann Oncol"},{"key":"2025040414261784300_qxaf051-B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.03.011","article-title":"Efficacy, safety, tolerability and price of newly approved drugs in solid tumors","volume":"56","author":"Barnes","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"2025040414261784300_qxaf051-B21","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamainternmed.2022.4924","article-title":"Association between US drug price and measures of efficacy for oncology drugs approved by the US food and drug administration from 2015 to 2020","volume":"182","author":"Miljkovi\u0107","year":"2022","journal-title":"JAMA Intern Med."},{"issue":"4","key":"2025040414261784300_qxaf051-B22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","article-title":"Five years of cancer drug approvals: innovation, efficacy, and costs","volume":"1","author":"Mailankody","year":"2015","journal-title":"JAMA Oncol"},{"issue":"5","key":"2025040414261784300_qxaf051-B23","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1200\/jop.17.00058","article-title":"Examining trends in cost and clinical benefit of novel anticancer drugs over time","volume":"14","author":"Saluja","year":"2018","journal-title":"J Oncol Pract."},{"issue":"5","key":"2025040414261784300_qxaf051-B24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/s1470-2045(20)30139-x","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025040414261784300_qxaf051-B25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40273-023-01320-4","article-title":"Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition","volume":"42","author":"Michaeli","year":"2023","journal-title":"PharmacoEconomics"},{"issue":"11","key":"2025040414261784300_qxaf051-B26","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.jval.2023.06.020","article-title":"Cancer drug prices in the United States: efficacy, innovation, clinical trial evidence, and epidemiology","volume":"26","author":"Michaeli","year":"2023","journal-title":"Value Health."},{"issue":"7","key":"2025040414261784300_qxaf051-B27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/s1470-2045(17)30415-1","article-title":"Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks","volume":"18","author":"Del Paggio","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025040414261784300_qxaf051-B28","article-title":"Best practices using SSR health net drug pricing data","volume":"March 10, 2022","author":"Ippolito","year":"2022","journal-title":"Health Affairs Forefront"},{"key":"2025040414261784300_qxaf051-B29","author":"SSR HEALTH"},{"key":"2025040414261784300_qxaf051-B30","author":"FDA"},{"issue":"10","key":"2025040414261784300_qxaf051-B31","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol."},{"issue":"9","key":"2025040414261784300_qxaf051-B32","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s11606-020-05805-2","article-title":"Orphan drugs offer larger health gains but less favorable cost-effectiveness than non-orphan drugs","volume":"35","author":"Chambers","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"9977","key":"2025040414261784300_qxaf051-B33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/s0140-6736(15)60742-5","article-title":"The history and fate of the gold standard","volume":"385","author":"Jones","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2025040414261784300_qxaf051-B34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"issue":"2","key":"2025040414261784300_qxaf051-B35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamainternmed.2016.7777","article-title":"Improving the accelerated pathway to cancer drug approvals","volume":"177","author":"Bauer","year":"2017","journal-title":"JAMA Intern Med."},{"key":"2025040414261784300_qxaf051-B36","doi-asserted-by":"publisher","first-page":"100332","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"eClinicalMedicine"},{"issue":"8","key":"2025040414261784300_qxaf051-B37","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1377\/hlthaff.2018.0221","article-title":"Prices for common cardiovascular drugs in the US are not consistently aligned with value","volume":"37","author":"Campbell","year":"2018","journal-title":"Health Aff."},{"issue":"9","key":"2025040414261784300_qxaf051-B38","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1377\/hlthaff.2022.00119","article-title":"Accelerated approval of cancer drugs: no economic reward for drug makers that conduct confirmatory trials","volume":"41","author":"Frank","year":"2022","journal-title":"Health Affairs (Project Hope)"},{"issue":"7","key":"2025040414261784300_qxaf051-B39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41571-018-0030-2","article-title":"Low-value approvals and high prices might incentivize ineffective drug development","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"issue":"7","key":"2025040414261784300_qxaf051-B40","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1257\/aer.20131176","article-title":"Do firms underinvest in long-term research? Evidence from cancer clinical trials","volume":"105","author":"Budish","year":"2015","journal-title":"Am Econ Rev"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxaf051\/62395947\/qxaf051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/4\/qxaf051\/62395947\/qxaf051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/4\/qxaf051\/62395947\/qxaf051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T15:05:37Z","timestamp":1743779137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxaf051\/8074216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxaf051","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,13]]},"article-number":"qxaf051"}}